The Manufacturers Life Insurance Company Acquires Shares of 174,061 Halozyme Therapeutics, Inc. $HALO

The Manufacturers Life Insurance Company purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 174,061 shares of the biopharmaceutical company’s stock, valued at approximately $13,624,000.

Other hedge funds have also recently added to or reduced their stakes in the company. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $27,000. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Halozyme Therapeutics during the second quarter worth $28,000. Measured Wealth Private Client Group LLC grew its holdings in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the period. Finally, Quantbot Technologies LP purchased a new position in Halozyme Therapeutics in the second quarter worth $30,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, August 14th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Morgan Stanley dropped their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $105.35 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market capitalization of $11.96 billion, a price-to-earnings ratio of 31.45, a PEG ratio of 0.43 and a beta of 0.85. The company’s 50 day simple moving average is $87.01 and its 200 day simple moving average is $74.78. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $109.66.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm posted $1.54 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 64,103 shares of company stock valued at $5,226,496 in the last three months. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.